# Diabetes Research Hub — Automated Iteration Report
**Date:** 2026-06-24 (Wednesday) · Run #71

## State at load
- **Papers:** 285 — all VETTED (272 clean / 13 FLAGGED legitimate off-topic). No vetting backlog.
- **Validated paths:** 56 · **Gaps:** 15 · **Work queue:** 23 items.
- Top queue item (p1) remains the **git push blocker — REQUIRES USER** (sandbox cannot authenticate/push; `.git/index.lock` cruft persists from prior runs).

## Work completed

### 1. Credibility sweep (every run) — CLEAN
- No fabricated PMIDs (>42,000,000) in any `.py` script.
- No "zero SAEs" / "zero rejection" claims in scripts.
- 3 "achieves" hits all legitimate and previously cleared: TTP399 tissue-selectivity *mechanism*, LADA cost-effectiveness *metric*, microbiome ML macro-AUC. The `verify_before_deploy.py` hits are the detector's own patterns.

### 2. Path re-validation (3 stalest PARTIALLY_VALIDATED) — all REAFFIRMED
| Path | Result | Basis |
|---|---|---|
| rituximab → T1D | REAFFIRMED PARTIALLY | Now backed by two independent 2025 SR/MA — network MA (PMC12211534, *Diabetologia*) and BMC Endocr Disord (s12902-025-02088-8), which document a transient C-peptide effect and a paradoxical dissociation between β-cell preservation and glycemic control. Tier unchanged. |
| tegoprubart_islet_t1d | REAFFIRMED PARTIALLY | ADA Scientific Sessions June 2026 + Eledon IR/HCPLive: all 12 UChicago pts insulin-independent, mean recent HbA1c ~5.4%, median/max follow-up 8/22 mo. **Still conference/press only — no peer-reviewed publication.** "No rejection / no de novo DSA" framing continues to mirror the doctrine "zero rejection" red flag; **not propagated as validated.** Next check 2026-08-02. |
| verapamil_T1D | REAFFIRMED PARTIALLY | Independently re-confirmed the **negative adult Ver-A-T1D primary** (n=136; 2 h MMTT C-peptide AUC no different vs placebo) vs the **positive pediatric CLVer** (~30% higher C-peptide). Age/onset heterogeneity stands. Already captured in state (Diabetologia doi:10.1007/s00125-025-06490-8) — this run independently corroborated it. |

### 3. Gap #1 audit (Gene Therapy for LADA, SILVER) — interim, ahead of 2026-06-29 due date
No LADA-specific gene-therapy clinical trial exists. CRISPR β-cell-protection work (e.g. genome-scale in vivo CRISPR identifying **RNLS** as a β-cell-protective target) remains **T1D-focused and preclinical**. 2025 LADA reviews (PMC9389314, PMC12522475) emphasize the residual-β-cell time window as rationale but cite no gene-therapy intervention. **Gap is genuine and VALID; stays SILVER** (no second independent LADA-specific source → not a promotion candidate). RNLS logged as a mechanistic watch-item. Next monthly audit ~2026-07-24.

### 4. Upcoming-readout early checks
- **Abata ABA-201** (TCR-Treg T1D): no first-in-human data yet; program initiating clinical studies, preclinical Treg data only. Rescheduled to 2026-08-02.

### 5. Pipeline rebuild (Step 5)
`run_quality_improvements.py` — **all 41 improvements [OK]**, including PMID verification against PubMed, citation/evidence-network validation, and Tufte-style site rebuild.

## State & queue
- `run_history` appended (now 71 runs); `topic_checks` updated with 4 entries; `last_path_validation_batch` set; `agent_state.json` saved (backup `agent_state.json.bak_2026-06-24`).
- Queue reprioritized: Gap #1 → ~2026-07-24; Abata/Tegoprubart → 2026-08-02; Ver-A-T1D → 2026-09-02 (primary already negative; watch secondary analyses); validate_path item now points to stalest remaining paths (teplizumab_long_term_followup, TXNIP_NLRP3_beta_cell_DKD, Treg_expansion→T1D).

## ⚠️ Action required from user
The repo cannot be committed/pushed from the sandbox (no GitHub auth; OneDrive blocks `unlink` so `.git/index.lock` cannot be cleaned). All files and state above are saved **locally only**. To sync, run from a local PowerShell terminal in the OneDrive copy:

```
del .git\index.lock
Get-ChildItem .git\index.* -Exclude index | Remove-Item -Force
git add -A
git commit -m "Daily iteration 2026-06-24: credibility sweep clean, 3 paths reaffirmed, Gap #1 audited, pipeline rebuilt"
git push
```

## Constraints honored
No fabricated PMIDs/citations/data · no overstated preclinical claims · all claims trace to a source · research synthesis, not medical advice.
